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Abstract: Over the last two decades, pharmacogenetics and pharmacokinetics have been increas-
ingly used in clinical practice in Psychiatry due to the high variability regarding response and side
effects of antipsychotic drugs. Specifically, long-acting injectable (LAI) antipsychotics have different
pharmacokinetic profile than oral formulations due to their sustained release characteristics. In
addition, most of these drugs are metabolized by CYP2D6, whose interindividual genetic variability
results in different metabolizer status and, consequently, into different plasma concentrations of
the drugs. In this context, there is consistent evidence which supports the use of therapeutic drug
monitoring (TDM) along with pharmacogenetic tests to improve safety and efficacy of antipsychotic
pharmacotherapy. This comprehensive review aims to compile all the available pharmacokinetic and
pharmacogenetic data regarding the three major LAI atypical antipsychotics: risperidone, paliperi-
done and aripiprazole. On the one hand, CYP2D6 metabolizer status influences the pharmacokinetics
of LAI aripiprazole, but this relation remains a matter of debate for LAI risperidone and LAI paliperi-
done. On the other hand, developed population pharmacokinetic (popPK) models showed the
influence of body weight or administration site on the pharmacokinetics of these LAI antipsychotics.
The combination of pharmacogenetics and pharmacokinetics (including popPK models) leads to a
personalized antipsychotic therapy. In this sense, the optimization of these treatments improves the
benefit–risk balance and, consequently, patients’ quality of life.
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1. Introduction
Schizophrenia is a severe mental disorder that is presented clinically heterogeneously
in patients. It is estimated that approximately 0.7–1% of the world population suffer from
this condition, currently affecting 24–25 million people worldwide according to data from
the World Health Organization [1–3]. Mainly, it causes disorder of behavior, thoughts, per-
ception and emotions. The core features are positive symptoms (delusions, hallucinations
and disorganized speech), negative symptoms (such as abulia, anhedonia and social with-
drawal), cognitive impairment (mainly in speed of mental processing, working memory
and executive functions) and affective symptoms (i.e., anxiety and depression) [4]. There
are well-defined instruments such as the Brief Psychiatric Rating Scale (BPRS), the Scale for
the Assessment of Positive Symptoms (SAPS), the Scale for the Assessment of Negative
Symptoms (SANS) or the Positive and Negative Symptoms Scale (PANSS) to measure
these positive and negative symptoms as well as general psychopathology. In clinical
studies, reductions in these scales have been used to define treatment response [5]. There
are several theories that try to explain the pathophysiology of this complex and highly poly-
genic disease, including brain structure defects or neurochemical alterations [6]. Recently
Genome Wide Association Studies have supported some of those classic neurochemical
hypotheses such as the dopaminergic and glutamatergic from a genetic perspective [7].
Nowadays, the pharmacological treatment of schizophrenia is based on antipsychotics, a
family of drugs which are classified into two separate groups: first generation or typical
(i.e., haloperidol, chlorpromazine) and second generation or atypical (i.e., risperidone,
paliperidone, aripiprazole). Both of them present affinity toward D2 receptors and reduce
positive symptoms. Atypical antipsychotics form a heterogenous group of drugs with
regard to their different receptor affinity. In addition to D2 receptor affinity, they have other
pharmacological actions involving different signaling pathways such as serotoninergic
receptors (5-HT2A,5-HT1A and 5-HT2C) that could be the main cause of their safer profile
compared to typical antipsychotics [8].
The effectivity of these drugs is far from expected. Treatment resistance requires dose
optimization that is based on a trial-and-error method caused by the current inability to
predict response to treatment; this added to severe and frequent adverse events are com-
monly the reasons that lead the patients to discontinue antipsychotic therapies. The main
handicap of oral antipsychotics formulations is adherence. Many factors have influence
on non-adherence such as forgetting doses of medication, adverse events during therapy
and poor insight that condition drug intake. According to various studies, which define
adherence as taking medication at least 75% of the time, non-adherence is around 50% of
treated patients [9,10]. This problem has been partially solved since typical long-acting
injectable (LAI) antipsychotics were released. Later, arrival of atypical LAI antipsychotics
introduced an improvement in the safety profile of these drugs, which are administered
at long intervals of time (from 2 weeks to 3 months). At this point, the tandem of phar-
macogenetics and pharmacokinetics plays a key role, and personalized prescription of
antipsychotics improves the safety and efficacy of pharmacotherapy. Combining pharma-
cogenetics with therapeutic drug monitoring (TDM) of LAI antipsychotics would be a great
tool to predict and anticipate patient response in order to achieve mental wellness and
minimize side effects. Furthermore, population pharmacokinetic (popPK) models should
be considered as a useful tool to understand the relationship between patient characteristics
and drug exposure.
Among all over the genes involved in pharmacokinetics of drugs, the Cytocrome P450
family is, by far, the most important in terms of interindividual variability. Most of drugs
that are commonly used in psychiatry are CYP2D6-dependent [11,12], an enzyme encoded
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from a highly polymorphic gene. Nowadays, there are already 145 alleles described for
CYP2D6. These alleles can have different functions, frequency and clinical impact on
metabolism across different populations [13–15]. Depending on allele combination, it is
possible to differentiate the following metabolizer status [16–21]: extensive or normal
metabolizer (EM/NM): their metabolic pathway is not altered; poor metabolizers (PM):
the activity enzyme is significantly reduced or absent; intermediate metabolizer (IM): those
who can metabolize substances in lower ratios compared to an EM but better than a PM.
Rapid or ultrarrapid metabolizer (UM): enzymatic hyperactivity compared to EM. Those at-
tracting more interest are PM, IM and UM due to their risk of developing adverse reactions
or lack of efficacy in clinical practice [22–24], so currently development in this area of knowl-
edge holds great promise for reducing time between diagnosis and seeking an effective
treatment. Lastly, a mismatch has been observed between the genotype-based prediction
of CYP450-mediated drug metabolism and the true capacity of an individual to metabolize
drugs (phenotype) due to non-genetic factors, which is called phenoconversion [25].
Compared to classical pharmacokinetics, where several samples at different time
points are collected from a patient to estimate their individual pharmacokinetic parameters
(clearance, distribution volume, half-life, etc.), population pharmacokinetics (popPK) ana-
lyzes the pooled data available of several patients in order to estimate pharmacokinetic
parameter values and their variance, identify covariates and study the random effects
(parameter variance which cannot be explained by covariates). All this information imple-
mented in a mathematical model (popPK models) plus Bayesian computational methods
allows us to estimate our patients’ individual pK parameters, which can be a very helpful
tool to individualize dosing and optimize the treatment efficacy and safety.
The three major prescribed LAI-antipsychotics are risperidone, paliperidone and arip-
iprazole, while LAI-olanzapine prescription has been decreasing over time [26]. Our aim is
to comprehensively review all the available literature about these three major prescribed
LAI-antipsychotics pharmacogenetics and pharmacokinetics, including the existing popPK
models as a crucial tool for predicting drug exposure, focusing on risperidone, paliperidone
and aripiprazole.
2. Long-Acting Risperidone
Risperidone is an atypical antipsychotic derived from benzisoxazole with potent
D2 and 5-HT2 receptor antagonism. LAI risperidone is an aqueous suspension of mi-
crospheres formed by a glycolic and lactic acid degradable matrix where risperidone
is encapsulated [27]. More recently, a new formulation of once-monthly subcutaneous
LAI risperidone has been approved by the FDA in which risperidone is suspended in
ATRIGEL®, a polymer that solidifies in contact with tissues [28,29].
2.1. Pharmacokinetics
Considering the physicochemical properties of polymers of risperidone, a reduced
release occurs a few days after injection (around 1% of the dose administered) followed by
a lag time of 3 weeks and then a significant release is observed in weeks 4–6 [27,30]. Due to
this lag phase, oral supplementation should be given in the first three weeks of treatment.
Metabolism of risperidone goes through hydroxylation and N-dealkylation processes in
which CY2D6 plays a predominant role in the formation of 9-OH-risperidone (9-OH-R),
main active and “equipotent” metabolite [31]. Product monograph states that the half-life
(t1/2) of risperidone plus 9-OH-R is 3–6 days [32] and the steady-state is reached after the
fourth injection and maintained for 4–5 weeks after the last injection [30]. As well as t1/2,
steady-states were determined by inspection of the concentration–time curve and not by
the rule of the five t1/2. As Lee et al. [33] point out, this can cause an underestimation of
the time when the steady state is reached and can lead to an increase in dosage and an
accumulation of the drug.
More recently, a new formulation of once-monthly subcutaneous LAI risperidone has
been approved by the FDA, in which risperidone is suspended in ATRIGEL®, a polymer
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that solidifies in contact with tissues, providing a sustained release. Risperidone ATRIGEL®
does not need oral supplementation due to its characteristic pharmacokinetic profile. After
subcutaneous injection, a first peak appears 4–6 h post-dose followed by a second one
10–14 days after. Steady state is reached by the end of the second injection and the apparent
half-life ranges between 8 and 9 days [28,29].
With regard to the therapeutic range of reference, the German working group for
neuropsychopharmacology and pharmacopsychiatry (AGNP) Consensus Guidelines for
Therapeutic Drug Monitoring established between 20 and 60 ng/mL for risperidone plus
9-OH-R [34]. This range is derived exclusively from orally given risperidone studies,
extrapolating this range to patients treated with long-acting formulations, which has not
yet been extensively studied. Two different studies used this AGNP range [35,36] but the
other two studies differ and propose other ranges for LAI risperidone [37,38]. De Leon
et al. [39] proposed an updated therapeutic range (20–30 ng/mL) for LAI risperidone
as a consequence of the prolonged absorption of LAI formulations and the reduction in
the administration frequency, which leads to less oscillations at steady-state conditions.
Despite this, until new data about LAI risperidone are available, the AGNP therapeutic
reference range is the most recommended [40].
2.2. Pharmacogenetics
2.2.1. Efficacy
Polymorphisms in the CYP2D6 gene could affect plasma concentrations of risperidone
plus 9-OH-R (active moiety) although the product monograph reflects that concentration
of the active moiety is the same in PM individuals as in other phenotypes [32]. Therefore,
adjusting the dose to the patient’s phenotype is not necessary but many published studies
differ on this point. It is suggested that CYP2D6 metabolizer status cause differences in
active moiety exposure and consequently in efficacy and tolerability, but there are still
controversies (Table 1).
Table 1. Studies between CYP2D6 phenotype and relation with active moiety exposure.




et al. [41] Oral 407 NR 38 267/140 PM/IM/NM Irrelevant
Scordo MG
et al. [42] Oral 37 Caucasians 41 30/7 PM/IM/NM/UM Irrelevant
Cho HY et al.
[43] Oral 24 Asian 24.6 NR PM/NM Irrelevant
Hendset, M
et al. [35] LAI 90 Caucasians 38 53/37 PM/IM/NM/UM
Relevant
(higher plasma exposure
for IM and PM)
Llerena A et al.
[44] Oral 35 Caucasians 43 NR PM/IM/NM/UM Irrelevant
Choong, E et al.
[45] LAI 42
Caucasian
(76%) 35 30/12 PM/IM/NM/UM
Relevant
(higher plasma exposure
for IM and PM and lower
for UM)
Leon, J. D et al.
[46] Oral 277
Caucasian





et al. [47] Oral 83 Caucasians 30.3 17/66 PM/NM/IM Irrelevant
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Table 1. Cont.
Study LAI/Oral n Race Age(Median) Male/Female
CYP2D6
Phenotypes Outcome
Jukic, M et al.
[48] Oral 725 Caucasians 42.8 355/370 PM/IM/NM/UM
Relevant
(higher plasma exposure
for IM and PM and lower
for UM)
Locatelli, I et al.
[49] LAI 50 Caucasian 30 39/11 PM/IM/NM/UM Irrelevant
Vandenberghe,
F et al. [50] Oral 150
Caucasian




Gunes, A et al.




Classified in relevant (significative association between CYP2D6 phenotype and active moiety exposure) or irrelevant (no significative
association between CYP2D6 phenotype and active moiety exposure or incorrect assignment of CYP2D6 genotype due to missing copy
number variation analysis). Abbreviations: PM, Poor Metabolizer; IM, Intermediate Metabolizer; NM, Normal Metabolizer; UM, Ultra
Metabolizer; NR: Not reported. Those studies that do not analyze the number of copies of the gene have been classified as irrelevant.
Among those classified as relevant, it is important to highlight that they should be taken as a guideline, taking into account that the main
limitation is the high heterogeneity that exists between the different methods of analysis used, as well as the polymorphisms explored in
the determination of the phenotype of CYP2D6.
A recent meta-analysis of 15 studies involving 2125 patients taking oral risperidone
concluded that CYP2D6 activity is associated with increased exposure of both risperidone
and active moiety. Risperidone steady-state plasma concentration was 2.35-fold higher in
IM and 6.20-fold higher in PM, while active moiety concentration was 1.18-fold higher in
IM and 1.44-fold higher in PM [52].
Furthermore, some studies suggest that PM are associated with a greater number
of adverse events and treatment discontinuation which decreases clinical efficacy [53,54].
In addition, some popPK models based on oral regimens of risperidone showed large
differences in CL/F depending on CYP2D6 phenotype. Mean CL/F values reported by
Feng et al. were 65.4, 36 and 12.5 L/h for EM, IM and PM, respectively [55]. The popPK
model developed by Sherwin et al. [56] obtained mean values of CL/F for EM, IM and
PM patients of 37.4, 29.2 and 9.38 L/h, respectively. Similar differences in CL/F between
PM (three-fold lower) and EM individuals were reported by Thyssen et al. [57] in a study
including pediatric and adult patients. More recently, a popPK model based on oral
regimen of risperidone showed that a reduced activity of CYP2D6 (PM) could increase up
to a 106% steady-state plasma concentration and up to a 53% higher Cmax compared with
NM, so dose adjustment may be necessary [58].
Nevertheless, LAI antipsychotics exhibit large differences compared to oral formu-
lations in terms of their PK profile due to their slow and sustained absorption. To our
knowledge, only a popPK LAI model of the risperidone ATRIGEL® formulation has been
published, which found body mass index and dose as covariates of absorption rate con-
stants and risperidone and 9-OH-R distribution volumes, respectively. In contrast, CYP2D6
polymorphisms were not statistically significant to any structural popPK parameter [59],
which might be explained by the unbalanced and reduced number of patients recruited.
It is possible to obtain approximated information about CYP2D6 activity using quan-
titative methods by the following ratios. On the one hand, the R/9-OH-R ratio (relates
risperidone and 9-OH-R plasma concentrations) values <1 are normal plasma ratios that
indicate normal CYP2D6 activity (UM, NM, IM) while a value >1 indicates a lack of activity
(PM) or the presence of a strong inhibitor [39,60,61]. On the other hand, total risperidone
C/D ratio is a measure of drug clearance that relates the concentration of the active moiety
with the dose of risperidone. The normal value for oral risperidone and for LAI formula-
tion is approximately around 7 ng/mL per mg/day and patients with ratios >14 ng/mL
per mg/day are expected to be CYP2D6 PM [40,60]. Previous procedures could be an
alternative for psychiatrists and could be a possibility for clinicians who do not have
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access to genotype CYP2D6, but it is important to take into account that these methods
would only be useful when CYP2D6 constitutes the main pathway of metabolization. It
is important to take into account that the CYP2D6 allele combination in a patient is an
invariable condition; once analyzed it will not change. Thus, analyzing polymorphisms
in CYP2D6 by pharmacogenetics can be useful to select the most appropriate drugs for
a patient, avoiding adverse effects or lack of efficacy concerning its CYP2D6 metabolizer
status. As a result, individualized treatment selection would become easier for prescribers.
Therefore, it seems clear that genetic variations in CYP2D6 have an impact on plasma
concentrations of risperidone, but there are controversies when it comes to relating it to
the efficacy of the treatment and clinical outcome. A study of 136 patients diagnosed
with schizophrenia and evaluating clinical improvement using the Positive and Negative
Syndrome Scale (PANSS) did not showed association between CYP2D6 activity variations
and clinical outcome [61]. Along the same line another study of 83 drug-naïve patients
experiencing a first episode of psychosis did not match the clear relation between CYP2D6
genetic variations and clinical improvement [47]. On the contrary, another study of 76
patients with schizophrenia evaluated changes on total PANSS and CYP2D6 polymorphism
founding correlation between PMs and better response to risperidone treatment. Only
three patients were classified as PMs but the power of the study was enough to establish
an association with PANSS improvement. [62]. Likewise, Jukic et al. recently identified a
higher incidence of therapeutic failure (discontinuation or switch to another antipsychotic)
in PMs [48]. These pharmacogenetic studies are based on oral risperidone administration
and not all of them had been conducted in patients with schizophrenia.
2.2.2. Safety
Antipsychotics can cause hyperprolactinemia by blocking dopaminergic receptors at
the tuberoinfundibular system [63]. Risperidone was reported to have a high prevalence
of hyperprolactinemia among all atypical antipsychotics [64,65]. Association between
CYP2D6 and hyperprolactinemia was described in a observational study of 47 children
and adolescents with autism spectrum disorder in a long-term treatment with risperidone;
the number of patients with hyperprolactinemia was 100% (2/2) for PM, 47% (8/17) for
IM, 48% (12/25) for NM and 0% (0/2) for UM [66]. Sex influence in hyperprolactinemia
incidence has been studied, observing a higher incidence in female than in males, a study
of Schoretsanitis et al. [67] involving 111 patients (61 males and 49 females) evaluates
association between CYP2D6 activity, risperidone levels and sex finding a significant
association across them. Another cause of reduced patient compliance is weight gain
produced by risperidone, relation between genetic polymorphisms and this adverse drug
reaction is still under study. Some studies like the one performed by Lane et al. found
significant association between CYP2D6×10 allele (PM) and weight gain but data about
this relation up-to-date are limited [68].
Extrapyramidal Symptoms (EPS) are the most evaluated adverse effects with CYP2D6
in a large number of studies. Nevertheless, it is not clear the impact of CYP2D6 variations
on EPS from risperidone. Several studies showed no significant difference between these
two variables and only a few find some correlation. Adverse effects were also examined
in a study of 70 healthy volunteers, several genes and respective polymorphisms were
associated with adverse effects (CYP2C9, NAT2, DRD2, CYP2C19) but no relation was
found between CYP2D6 polymorphisms and EPS [69]. De Leon et al. [53] showed this
association in 73 patients with moderate to severe EPS and 81 patients that discontin-
ued risperidone due to EPS. CYP2D6 PM phenotype was associated with the first group
(OR = 3.4; CI = 1.5–8.0, p = 0.004) and with the second group. (OR = 6; CI = 1.4–25.4,
p = 0.02). Another recent study evaluated 22 patients and the Drug-induced Extrapyrami-
dal Symptoms Scale (DIEPSS) score; they observed that DIEPSS score was significantly
higher in the IM group (7) than in the EM group (15) [70]. A summary of LAI-risperidone
pharmacokinetic and pharmacogenetic characteristics is available in Table 2.
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Abbreviations: Tmax, time to maximum concentration after administration; Tss, time to reach steady state; t1/2, apparent half-life of
elimination. TDM Levels of recommendation: 1: Strongly recommended; 2: Recommended; 3: Useful; 4: Potentially useful (33). Genetic test;
informative: the label contains information stating that a particular gene affects or does not effect drug efficacy, not clinically significant.
3. Long-Acting Paliperidone
Paliperidone (9-OH-Risperidone) is the primary active metabolite of risperidone.
This long-acting drug is formulated as a palmitate ester of paliperidone in an aqueous
suspension of nanocrystals resulting in a sustained release profile [71,72]. This technology
confers an increased solubility, absorption and bioavailability [73]. Monthly formulation
(PP1M) was approved by the FDA in 2009 and trimestral formulation (PP3M) in 2015,
a semi-annual formulation is currently being developed [74]. For developing PP3M,
the manufacturer used a PP1M population-pharmacokinetic model and avoid phase II
study [75]. The main difference between PP1M and PP3M is that this last one has an
increased particle size what allows its longer sustained release [76].
3.1. Pharmacokinetics
Paliperidone palmitate is slowly dissolved at the injection site after the intramuscular,
deltoid or gluteal, administration and then rapidly hydrolyzed. Peak plasma concentration
is achieved 13 days after injection while steady-state conditions last nearly 8 months. The
apparent half-life ranges between 25 and 49 days. In contrast to risperidone, paliperidone
is not extensively metabolized in the liver and nearly half of the dose is excreted unchanged
in urine, so dose reduction is recommended in patients with mild renal impairment [71].
LAI Paliperidone treatment is not recommended in patients with moderate to severe
renal impairment.
A popPK model of LAI PP1M statistically identified BMI, creatinine clearance, injec-
tion site (deltoid vs. gluteal), injection volume and needle length as statistical covariates,
demonstrating that administration procedure and the site of injection play a key role on
PP1M pharmacokinetic profile [77]. The summary of product characteristics recommends
a first deltoid injection of 234 mg of paliperidone palmitate followed by a second deltoid
injection of 156 mg one week later [71]. Different studies evaluated therapeutical equiva-
lence of deltoid versus gluteal injection sites. While some authors stated that differences
between deltoid and gluteal injection are not clinically relevant [78], Yin et al. reported that
it can compromise maintenance treatment [79]. A case report observed that absorption rate
after gluteal injection decreased in obese patients due to subcutaneous fat [80]. According
to this, another study estimates that time to reach steady-state differs by 4 weeks between
deltoid (38w) and gluteal (42w) injection [81]. It seems that deltoid injection provides
better absorption so it should be chosen instead of the gluteal zone whenever is possible,
especially in obese patients.
On the other hand, PP3M is approved for use in patients previously treated with
PP1M formulation for at least 4 months with a dose 3.5 times higher than the previous
PP1M dosage. PP3M has a larger particle size compared to PP1M, which allows for longer
sustained release and administration every 3 months. Peak plasma concentrations are
achieved 30–33 days after administration while consecution of steady-state lasts nearly
15 months. Apparent half-life ranges from 84 to 95 days (deltoid administration) versus 118
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to 139 days (gluteal administration). This difference in half-life of PP3M depending on site
of injection could be due to flip-flop kinetics that occur on these long-acting formulations.
According to Schoretsanitis et al., urgent real-world half-life studies are needed in steady-
state conditions to clarify dose-dependent half-lives on dose and influence of injection
site [40]. The most relevant parameters of the popPK models of PP1M and PP3M are
summarized in Table 3.
Table 3. Population pharmacokinetic models of paliperidone palmitate.





- Dual and sequential input
absorption: rapid zero order
followed by first-order
absorption after a lag time.
- Flip-flop kinetics due to
dissolution rate limited
absorption.
- SEX, AGE, IVOL
and INJS on Ka
- CLCR on CL













SEX = 1 for males
SEX = 0.726 for females
Magnusson
et al. [82] LAI-PP3M
- One-compartment model
with first-order elimination
- Dual and sequential input
absorption processes: rapid
zero absorption followed by
first-order absorption.
- IVOL on Ka
- INJS and SEX on
Kamax
- CLCR on CL












Abbreviations: LAI: long-acting injectable. PP1M: once-monthly paliperidone palmitate. PP3M: once every 3 months paliperidone
palmitate. IVOL: injection volume. INJS: injection site. BMI: body mass index. NDLL: needle length. KA: first-order absorption rate
constant. Kamax: maximum absorption rate. CL: clearance. VD: apparent volume of distribution. CL/F: clearance relative to bioavailability
(in the absence of intravenous administration). VD/F: apparent volume of distribution relative to bioavailability (in the absence of
intravenous administration).
With regard to the reference range, AGNP consensus guidelines established the
paliperidone palmitate reference range between 20 and 60 ng/mL, but this range is again
an extrapolation from oral paliperidone studies and discordance exists. A study of non-
steady-state patients revealed that 45% of them were under the AGNP range [83]; on the
other hand, two different studies agreed with the AGNP therapeutic range [84,85].
3.2. Pharmacogenetics
Metabolism and elimination information provided by the manufacturer are based on
a study of five healthy male subjects given a 1 mg single dose of 14C-paliperidone oral
solution; 59% of the dose was excreted unchanged in urine. They identified four metabolic
pathways but none of them metabolized more than 6.5% of the dose. Three subjects were
classified as EM and two were classified as PM for CYP2D6 using the dextrometorphan
metabolic ratio. No differences in the overall plasma pharmacokinetics were observed
between EM and PM. A total of 80% of the administered radioactivity was recovered in
urine and 11% in the feces [86]. The small sample size (n = 5) of the study and the fact
of oral administration instead of injectable does not make it possible to draw definitive
conclusions with a sufficient level of evidence. Another study including 31 patients treated
with paliperidone (Oral: 9 LAI: 22) did not find a statistical difference in either for the C/D
ratios between different CYP2D6 phenotypes (4 PM, 3 IM, 22 EM, 2 UM) [87]. A summary
of LAI-paliperidone pharmacokinetic and pharmacogenetic characteristics is available in
Table 4.
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Abbreviations: Tmax, time to maximum concentration after administration; Tss, time to reach steady state; t1/2, apparent half-life of
elimination. TDM Levels of recommendation: 1: Strongly recommended; 2: Recommended; 3: Useful; 4: Potentially useful (33). Genetic
test; informative: label contains information stating that a particular gene affects or does not affect drug efficacy, not clinically significant.
With these data it is expected that co-treatment with cytochrome inducers does
not play any role in metabolism of paliperidone; however, a study performed by Yasui-
Furukori et al. [88] in steady-state conditions observed that paliperidone concentrations
decrease nearly 48% when carbamazepine, a potent CYP3A4 inductor, was administered
concomitantly. Due to the lack of evidence regarding the influence of CYP2D6 polymor-
phisms in paliperidone plasma concentrations (Table 5), it is not expected that it could be
associated with a higher risk of adverse effects.
Table 5. Studies between CYP2D6 phenotype and the relation with paliperidone plasma exposure.




[86] Oral 5 Caucasian 51 5/0 PM/NM * Irrelevant
Lisbeth et al.
[87] Oral/LAI 31 Caucasian 35 22/9 PM/IM/EM/UM Irrelevant
Berwaerts
et al. [89] Oral 60
Caucasian




Irrelevant outcome (no significative association between CYP2D6 phenotype and paliperidone plasma exposure or incorrect assignment of
CYP2D6 genotype due to missing copy number variation analysis). Abbreviations: PM, Poor Metabolizer; IM, Intermediate Metabolizer;
NM, Normal Metabolizer; UM, Ultra Metabolizer; NR: Not reported. * Phenotyped using the dextromethorphan metabolic ratio.
4. Long-Acting Aripiprazole
Aripiprazole was the first antipsychotic to have partial agonist effects at D2 receptors.
This property, plus D3 and 5-HT1A partial agonism and 5-HT2A receptor antagonism
translates, into a reduction in negative, positive and cognitive symptoms of schizophrenia,
minimizing the risk of some adverse effects compared with other atypical antipsychotics.
4.1. Pharmacokinetics
The aripiprazole once monthly (AOM) long-acting injectable is the monohydrate
polymorphic form of aripiprazole [90]; currently, doses of 400 mg and 300 mg are approved
for induction (along with 14 days of oral supplementation) and maintenance therapy of
schizophrenia. Recently, an induction start of two injections of 400 mg has been approved,
avoiding the need for oral supplementation for 14 days [90]. Due to low solubility, AOM
absorption into the systemic circulation is slow and prolonged after intramuscular injection.
Peak plasma concentration is reached after 4 days in deltoid injection versus 5–7 days in
gluteal injection, in steady-state conditions. The mean apparent half-life is 29.9 days for
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300 mg and 46.5 days for 400 mg; steady-state concentrations are achieved by the fourth
injection for both sites of injection according to the manufacturer [90,91].
Systemic metabolism is carried out mainly by liver biotransformation, mediated by
CYP3A4 and CYP2D6, yielding to its main active metabolite dehydro-aripiprazole [92].
Dehydro-aripiprazole is also a ligand at the D2 receptor and has similar pharmacological
properties to the original compound [93]. At steady state, this metabolite represents
up to 40% of plasma drug concentration [94]. Therefore, both compounds are thought to
contribute to the antipsychotic effects. As well as risperidone and paliperidone, aripiprazole
and dehydro-aripiprazole are substrates of P-gp [95]. In this case, to our knowledge
no literature is available about binding affinity to P-gp of aripiprazole and dehydro-
aripiprazole.
Recently, the new lauroxil LAI aripiprazole formulation has been approved. After
intramuscular injection, aripiprazole lauroxil slowly dissolves and it is then hydrolyzed to
aripiprazole. Peak plasma concentrations are achieved 41 days post-dose, while the steady-
state is reached after 4 months. Supplementation with oral aripiprazole is needed 21 days
after first administration. A 1-day regimen composed of 30 mg oral aripiprazole plus an
intramuscular 675 mg nanocrystalline aripiprazole has also been approved. Aripiprazole
lauroxil can be after administrated every 4, 6 or 8 weeks depending on the dose.
Therapeutic reference range based on oral formulation studies were reported between
100 and 350 ng/mL for aripiprazole and 150 and 500 ng/mL for the active moiety (arip-
iprazole plus dehydro-aripiprazole) [34]. AOM 400 mg provided sustained mean plasma
concentrations comparable to those achieved by oral aripiprazole, 10–30 mg/day at steady-
state. These data were evaluated in a 24-week, open-label, phase I study conducted in
41 patients with schizophrenia, receiving oral supplementation with 10 mg of aripiprazole
for the first 14 days following the initial injection [91,96]. Pharmacokinetic data about AOM
are to date limited; no third-party studies with PK analysis are available.
A study performed by the manufacturer comparing deltoid and gluteal administration
verified that exposure was similar between the two injection sites but absorption rate and
Cmax were higher in the deltoid group; it seems that, as in other LAI antipsychotics, deltoid
administration is a better injection site [96].
Most relevant parameters of the popPK models of aripiprazole lauroxil are summa-
rized in Table 6, which simultaneously modeled aripriprazole and dehydro-aripriprazole
observations. Surprisingly, factors related with its administration (needle length or in-
jection volume) were not statistically significant covariates in LAI-aripiprazole lauroxil
pharmacokinetics, in contrast to PP1M and PP3M findings. CYP2D6 and total weight
significantly affected LAI-aripiprazole pharmacokinetics.
Table 6. Population pharmacokinetic model of LAI aripiprazole.







absorption followed by a
first-order process
- Zero-order conversion of
aripiprazole lauroxil to
aripiprazole
- CYP2D6 PM on
CL














Abbreviations: KA: first-order absorption rate constant. CL/F: clearance relative to bioavailability (in the absence of intravenous
administration). VD/F: apparent volume of distribution relative to bioavailability (in the absence of intravenous administration).
4.2. Pharmacogenetics
The FDA recommends dose adjustment for aripiprazole in patients who are known
CYP2D6 PMs and AOM product monograph recommends an adjusted dose of 300 mg
for this group of patients [90]. According to these data, C/D ratios observed in 62-patient
study treated with oral aripiprazole indicated that PMs typically need 30–40% lower
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doses to achieve similar serum concentrations as NMs [98]. As aripiprazole and dehydro-
aripiprazole are regarded as equipotent [93], Suzuki et al. [99] in a study of 89 healthy
patients demonstrated that subjects with any or reduced functional alleles (×5 and ×10)
for CYP2D6 had higher C/D ratios of the active moiety of the two compounds than those
without the alleles. In a recent retrospective cohort study including pharmacokinetic data
of 890 patients it was found that aripiprazole active moiety exposure increased 1.6 times
and 1.4 times for PMs and IMs, respectively [48]. All these data and those of other studies
are available in Table 7, showing the necessary dose adjustment in PMs.
Table 7. Studies between CYP2D6 phenotype and the relation with aripiprazole plasma exposure.




[99] Oral 89 Asian 38 46/43 IM/NM/UM
Relevant
(higher plasma exposure
for IM and PM)
Suzuki et al.




[54] Oral 266 Caucasian 33 NR IM/NM Irrelevant
Hendset et al.





et al.* [101] Oral 148 Caucasian 26 85/63 PM/IM/NM/UM
Relevant
(higher plasma exposure




(469/166) Caucasian 40 294/341 PM/IM/NM/UM
Relevant
(higher plasma exposure
for PM and IM)
Jukic et al.
[48] Oral 890 Caucasian 37 400/490 PM/IM/NM/UM
Relevant
(higher plasma exposure
for PM and IM)
Lisbeth et al.







Oral 130 Caucasian NR NR PM/IM/NM/UM Irrelevant
Azuma





[105] Oral 20 Asian 24 20/0 IM/NM Irrelevant
Classified in relevant (significative association between CYP2D6 phenotype and active moiety exposure) or irrelevant (no significative
association between CYP2D6 phenotype and active moiety exposure or incorrect assignment of CYP2D6 genotype due to missing copy
number variation analysis). Abbreviations: PM, Poor Metabolizer; IM, Intermediate Metabolizer; NM, Normal Metabolizer; UM, Ultra
Metabolizer; NR: Not reported. * Those studies which do not analyze the number of copies of the gene have been classified as irrelevant.
Among those classified as relevant, it is important to highlight that it should be taken as a guideline, taking into account that the main
limitation is the high heterogeneity that exists between the different methods of analysis used, as well as the polymorphisms explored in
the determination of the phenotype of CYP2D6. ** Single-dose study.
Current FDA recommendation only takes into account dose adjustment in CYP2D6
PMs, but available studies show that dose reduction should also be carried out in CYP2D6
IMs. In this sense, Tveito et al. [102] established that IM phenotype increases aripiprazole
plasma concentration by 50% and active moiety concentration by 40%, both compared to
NM. Further pharmacogenetic studies must be carried out in order to confirm this effect
on plasma exposure, which could entail updating the product information regarding this
group of patients. Among all the studies, only a few of them were performed with AOM, in
which substantial influence of CYP2D6 phenotype on serum concentrations was observed
too, as in oral formulations [102].
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Aripiprazole is generally well tolerated due to its good safety profile concerning
extrapyramidal reactions which are less common than in the other atypical antipsychotics,
except for akathisia [106,107]. Hendset et al. [98] observed that CYP2D6-defective alleles
patients were associated with more potent adverse effects. In addition, a case–control
study with eight patients suggested that IM and PM CYP2D6 status are more frequently
associated with extrapyramidal reactions [108]. Another study found that PM and IM were
associated with higher incidence of nausea/vomiting due to higher plasma concentrations
of aripiprazole in these subjects [101]. A summary of LAI-aripiprazole pharmacokinetic
and pharmacogenetic characteristics is available in Table 8.

























400 mg: 46.5 days















Abbreviations: Tmax, time to maximum concentration after administration; Tss, time to reach steady state; t1/2, apparent half-life of
elimination. TDM Levels of recommendation: 1: Strongly recommended; 2: Recommended; 3: Useful; 4: Potentially useful (33). Genetic test;
Informative: this label contains information stating that a particular gene affects or does not affect drug efficacy, not clinically significant;
Actionable: this label may contain information about changes in efficacy due to gene variants.
Only a few of the summarized studies are developed using LAI formulations of an-
tipsychotics; there is an urgent need for independent and real-world LAI antipsychotics
TDM studies to clarify pharmacokinetic data such as the half-life and therapeutic refer-
ence range.
5. Pharmacokinetics/Pharmacogenetics Implementation
Pharmacogenetics can also contribute to understand antipsychotics behavior in the
organism, and this information can be totally complemented with pharmacokinetics data
of LAI. The use of pharmacogenetics on treatment optimization is exemplified in different
case reports [109–111]. Moreover, nowadays there are multiple initiatives that are already
translating pharmacogenetics into clinical care around the world. To cite several examples,
there is the Electronic Medical Records and Genomics (eMERGE-PGx) and St. Jude Chil-
dren’s Research Hospital that are using pharmacogenetic analysis to guide treatment in
patients; both initiatives are from the United States [112,113]. In Europe, the Ubiquitous
Pharmacogenomics project (U-PGx) can be found, with seven countries taking part, one
of them Spain [114]. In our country, there are already hospitals incorporating pharmaco-
genetics into health services [115]. There is also a Pharmacogenomic Society, the Spanish
Society of Pharmacogenetics and Pharmacogenomics (SEFF), which is actively working
on promoting pharmacogenetics knowledge and developing guidelines for healthcare
professionals [116].
Viability of pharmacogenetics testing in psychiatry has been observed. Five years ago,
two different studies were performed where physicians were asked about pharmacogenet-
ics in psychiatry practice. Around 95% of the physicians believe that this can help them
and their patients in decision-making [117] and 80–85% think that pharmacogenetics will
become a standard practice in the future [117,118], which is currently a reality as afore-
mentioned [119]. Curiously, in 2012 Mas et al. [120] studied CYP2D6 polymorphisms in
151 patients treated with risperidone and realized that PMs received the lowest doses and
UM the higher doses, without physicians knowing patients’ metabolic status. However, a
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preventive pharmacogenetics test would resolve the casuistry with better cost-effectiveness
for the health care system and the patient versus traditional prescribing methods [121].
As we have mentioned, schizophrenia implies a great economic cost for health care
systems, families and society. A study performed in patients with psychiatric conditions
taking drugs not recommended based on genetic information showed that they have 69%
more total health care visits, 67% more medical visits and three times more medical absence
days compared to patients taking drugs recommended based on their genotypes [122].
Another study associated CYP2D6 PMs and UMs to longer hospital stay duration compared
to EMs [123]. In 2013, Herbild et al. [124] demonstrated cost-effectiveness of preemptive
CYP2D6 or CYP2C19 genotyping in patients with schizophrenia. TDM and preemptive
genotyping of patients could reduce the time spent seeking the right antipsychotic drug
and dose, minimizing hospital stay and visits, preventing adverse drug reactions and
reducing associated costs. To all of these expenses must be added the expensive treatment
with LAI, so studies focused on therapies with this group of drugs are needed to assess the
cost–benefit ratio of preemptive CYP2D6 genotyping.
6. Unsolved Questions and Future Directions
According to the LAI risperidone product monograph, 9-OH-R has similar phar-
macological activity to risperidone [32]; however, oral paliperidone has been approved
with twice the daily dose of risperidone. Accordingly, de Leon et al. [60,125] suggest that
risperidone is twice as potent as paliperidone. In this sense, brain imaging studies showed
that lower doses of risperidone cause a similar percentage of binding to higher doses of
paliperidone [126,127]. This could be explained by the high affinity of paliperidone to P-gp,
minimizing blood–brain barrier (BBB) penetration.
The correlations between plasma and brain concentration for risperidone and 9-OH-R
have been studied by Aravagiri et al. [128] in rats documenting differences in the distribu-
tion of both compounds in the brain, showing plasma/brain ratios of 6.7 for risperidone
and 32.9 for 9-OH-R. These differences could be explained by two different factors: first,
affinity of risperidone and 9-OH-R for P-glycoprotein (P-gp) in BBB. Wang et al. [129] con-
ducted a study in abcb1a/b knockout mouse model dysfunctional in P-gp. Data showed
that the ratio of plasma to brain of 9-OH-R was 2.4-fold higher than that for risperidone.
This could mean that 9-OH-R presents a higher affinity for P-gp than risperidone and it
could explain the greater toxicity of risperidone than 9-0H-R [60]; second, hydroxylation of
risperidone to 9-OH-R makes it more hydrophilic, decreasing the ability to cross the BBB.
A preliminary assessment has demonstrated the prediction performance of D2/3
receptor occupancy a priori to optimize the dosing regimen based on risperidone blood
concentrations. Accordingly, a 65–80% D2/3 receptor occupancy is associated with maxi-
mal effectiveness, minimal risk of adverse events and reduced risk of relapse in patients
receiving supra-therapeutic doses [130]. Similar D2/3 receptor occupancy was also re-
ported by Shin et al. after aripiprazole administration, demonstrating the improvement of
the cognitive function in a small sample size of patients with schizophrenia [131]. Therefore,
predictive popPK models are encouraged to better characterize the PK properties of LAI
antipsychotics and identify the sources of inter-individual variability in order to establish a
PK/PD framework able to assess D2/3 receptor occupancy. The mathematical framework
would allow the evaluation of dosing strategies in special sub-groups of patients, which
will help to achieve an optimal efficacy/safety balance.
7. Conclusions
Atypical LAI have resulted in a great increase in safety compared with the previously
available typical LAI. However, limited evidence has restricted the proper characterization
of their pharmacokinetic properties, specifically regarding LAI of risperidone, paliperi-
done and aripiprazole. The role of CYP2D6 has been demonstrated on the PK of LAI
aripriprazole, although it remains uncertain for LAI risperidone and LAI paliperidone. In
spite of that fact, the developed popPK models showed common aspects regarding the
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influence of body weight, administration site and needle characteristics on the pharma-
cokinetic behavior of these drugs. However, the reduced number of patients enrolled, the
prolonged drug half-life and the limited number of clinical studies available may limit the
identification of covariates and pharmacogenetic effects that would help to explain the
large inter-individual differences concerning drug exposure. Pharmacogenetic analysis
should be considered with caution because the CYP2D6 polymorphisms analyzed in each
study are different. Assuming that all the polymorphisms that were not analyzed are
wild-type allele; consequently, exceedance of NM would be obtained. The CYP2D6 gene is
a complex gene, which presents duplications, deletions and even non-functional hybrids
and, therefore, requires a more exhaustive approach to be able to determine the relationship
between kinetics and genetics. Additional evaluations, including continuous PK endpoints,
are encouraged to provide a more comprehensive characterization of the PK/PD properties
of LAI in order to guide the individual dose selection.
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Polymorphisms In Patients Using Long-Acting Injectable Risperidone. Clin. Ther. 2016, 38, e10–e11. [CrossRef]
38. Nesvåg, R.; Tanum, L. Therapeutic Drug Monitoring of Patients on Risperidone Depot. Nord. J. Psychiatry 2005, 59, 51–55.
[CrossRef]
39. de Leon, J. Personalizing Dosing of Risperidone, Paliperidone and Clozapine Using Therapeutic Drug Monitoring and Pharmaco-
genetics. Neuropharmacology 2020, 168, 107656. [CrossRef]
40. Schoretsanitis, G.; Spina, E.; Hiemke, C.; de Leon, J. A Systematic Review and Combined Analysis of Therapeutic Drug Monitoring
Studies for Long-Acting Risperidone. Expert Rev. Clin. Pharmacol. 2017, 10, 965–981. [CrossRef]
Pharmaceutics 2021, 13, 935 16 of 19
41. Vermeulen, A.; Piotrovsky, V.; Ludwig, E.A. Population Pharmacokinetics of Risperidone and 9-Hydroxyrisperidone in Patients
with Acute Episodes Associated with Bipolar I Disorder. J. Pharm. Pharm. 2007, 34, 183–206. [CrossRef] [PubMed]
42. Scordo, M.G.; Spina, E.; Facciolà, G.; Avenoso, A.; Johansson, I.; Dahl, M.L. Cytochrome P450 2D6 Genotype and Steady State
Plasma Levels of Risperidone and 9-Hydroxyrisperidone. Psychopharmacology 1999, 147, 300–305. [CrossRef]
43. Cho, H.-Y.; Lee, Y.-B. Pharmacokinetics and Bioequivalence Evaluation of Risperidone in Healthy Male Subjects with Different
CYP2D6 Genotypes. Arch. Pharm Res. 2006, 29, 525–533. [CrossRef] [PubMed]
44. Llerena, A.; Berecz, R.; Dorado, P.; de la Rubia, A. QTc Interval, CYP2D6 and CYP2C9 Genotypes and Risperidone Plasma
Concentrations. J. Psychopharmacol. 2004, 18, 189–193. [CrossRef]
45. Choong, E.; Polari, A.; Kamdem, R.H.; Gervasoni, N.; Spisla, C.; Sirot, E.J.; Bickel, G.G.; Bondolfi, G.; Conus, P.; Eap, C.B.
Pharmacogenetic Study on Risperidone Long-Acting Injection: Influence of Cytochrome P450 2D6 and Pregnane X Receptor on
Risperidone Exposure and Drug-Induced Side-Effects. J. Clin. Psychopharmacol. 2013, 33, 289–298. [CrossRef]
46. De Leon, J.; Susce, M.T.; Pan, R.-M.; Wedlund, P.J.; Orrego, M.L.; Diaz, F.J. A Study of Genetic (CYP2D6 and ABCB1) and
Environmental (Drug Inhibitors and Inducers) Variables That May Influence Plasma Risperidone Levels. Pharmacopsychiatry 2007,
40, 93–102. [CrossRef] [PubMed]
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